知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

42 条记录 (耗时 0.021 秒)

    Epithelial Treatment
    22.
    发明申请
    Epithelial Treatment 审中-公开

    公开(公告)号：US20170326176A1

    公开(公告)日：2017-11-16

    申请号：US15528395

    申请日：2015-11-24

    申请人： Anant SHARMA

    发明人： Anant SHARMA

    IPC分类号： A61K35/14 ,  A61K9/00 ,  A61K38/01 ,  A61K8/98 ,  A61K35/60 ,  A61K47/38

    CPC分类号： A61K35/14 ,  A61F9/00 ,  A61K8/983 ,  A61K9/0014 ,  A61K9/0048 ,  A61K9/006 ,  A61K35/60 ,  A61K38/014 ,  A61K38/017 ,  A61K47/36 ,  A61K47/38 ,  A61Q11/00

    摘要： Products are described for treating epithelial tissues of the human or animal body including liquid compositions containing whole blood, or parts of blood including blood plasma, blood serum, blood platelets and growth factors derivable from blood. Other compositions disclosed include solid reservoirs of collagen or amniotic membrane into which whole blood or parts of blood have been absorbed. Methods of treatment using these compositions are described, in particular for treatment of ophthalmic disorders such as dry-eye and oral disorders such as dry mouth. A range of devices (1, 11, 31, 41, 51, 61, 71, 81, 91, 101) are described for sampling, mixing, storing and/or applying blood and compositions containing blood and parts of blood.

    Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Dengue Virus Infection
    23.
    发明申请
    Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Dengue Virus Infection 审中-公开

    公开(公告)号：US20170275338A1

    公开(公告)日：2017-09-28

    申请号：US15471098

    申请日：2017-03-28

    申请人： Emergex Vaccines Holdings Limited

    发明人： Ramila Philip

    IPC分类号： C07K14/005 ,  A61K38/19 ,  A61K39/12

    CPC分类号： C07K14/005 ,  A61K38/017 ,  A61K38/19 ,  A61K39/12 ,  A61K2039/55522 ,  C12N2770/24134 ,  Y02A50/386

    摘要： Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines.

    Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Dengue Virus Infection
    25.
    发明申请
    Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Dengue Virus Infection 有权
    细胞毒性T淋巴细胞诱导免疫原，用于预防登革热病毒感染的治疗和诊断

    公开(公告)号：US20140105925A1

    公开(公告)日：2014-04-17

    申请号：US14116899

    申请日：2012-06-28

    申请人： Immunotope, Inc.

    发明人： Ramila Philip

    IPC分类号： C07K14/005

    CPC分类号： C07K14/005 ,  A61K38/017 ,  A61K38/19 ,  A61K39/12 ,  A61K2039/55522 ,  C12N2770/24134 ,  Y02A50/386

    摘要： Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines.

    摘要翻译： 登革热（DF）和登革出血热（DHR）是全球重要的公共卫生问题，了解感染的整体免疫反应将有助于该疾病的适当管理及其潜在的严重并发症。 活体减毒和亚单位疫苗候选人，正在进行临床评估，主要诱导对病毒的抗体应答和最小的交叉反应性T细胞应答。 目前，没有可用的工具来评估感染或疫苗接种后的保护性T细胞应答。 本发明包括免疫蛋白组学以揭示衍生自登革病毒（DV）感染细胞的新型HLA-A2特异性表位。 这些表位与表位特异性CTL保守，与所有四种DV血清型交叉反应。 这些表位具有潜在的新信息和诊断工具，用于表征登革病毒（DV）感染中的T细胞免疫，并且作为与当前疫苗互补的通用疫苗候选者。

    Preparation of a therapeutic composition
    28.
    发明授权
    Preparation of a therapeutic composition 有权
    治疗组合物的制备

    公开(公告)号：US06303153B1

    公开(公告)日：2001-10-16

    申请号：US09344095

    申请日：1999-06-25

    申请人： Bernard Friedland ,  Shalom Z. Hirschman

    发明人： Bernard Friedland ,  Shalom Z. Hirschman

    IPC分类号： A61K3801

    CPC分类号： A61K38/014 ,  A61K38/011 ,  A61K38/017 ,  A61K38/018 ,  A61K2300/00

    摘要： Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises nucleotides and peptides that have molecular weights not more than 14 KDa and substantially not more than 8 KDa. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 nm/280 nm and 1.359 at 260 nm/230 nm.

    摘要翻译： 产品R是用于治疗病毒感染和刺激免疫系统的新型治疗组合物，其包含分子量不超过14KDa且基本上不超过8KDa的核苷酸和肽。 该组合物具有吸光光谱，在260nm / 280nm处的典型吸收比为1.998，在260nm / 230nm处为1.359。